Live Analyst Rating Changes 24938 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/David Roman
GS

David Roman

Goldman Sachs
Wall Street Analyst
★★★★☆
#504
on 13Foresight · ranked by our own returns
66%
Success Rate
+10.1%
Average Return
31 of 47 calls profitable · +3.8% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 66% of David Roman's ratings turned a profit when each position was held for 1 year — averaging +10.1% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

68 Buy 40 Hold 11 Sell
David's Stock Coverage 33 ratings · 2026-08-14
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
BBNX
Beta Bionics, Inc.
 Jul 15, 2026 BUY Strong Buy
+20.9% avg upside
14 analysts
$19.00
5.17% Upside
 +4.2% ·
BAX
Baxter International
 Jul 15, 2026 HOLD Buy
+23.8% avg upside
23 analysts
$21.00
22.29% Downside
 +22.1% ·
BSX
Boston Scientific
 Jul 14, 2026 BUY Strong Buy
+31.1% avg upside
38 analysts
$57.00
10.18% Upside
 +20.6% ·
MOBI
Mobia Medical, Inc.
 Jul 14, 2026 BUY Strong Buy
+77.6% avg upside
4 analysts
$31.00
165.35% Upside
 +1.6% ·
BLCO
Bausch + Lomb Corporation
 Jul 14, 2026 HOLD Buy
+17.5% avg upside
19 analysts
$21.00
23.69% Upside
 +6.8% ·
TNDM
Tandem Diabetes Care
 Jul 14, 2026 HOLD Buy
+41.5% avg upside
29 analysts
$16.00
30.76% Downside
 +46.2% ·
EW
Edwards Lifesciences
 Jun 15, 2026 BUY Strong Buy
+8.5% avg upside
34 analysts
$98.00
5.89% Upside
 +6.2% ·
ISRG
Intuitive Surgical
 Jun 15, 2026 BUY Strong Buy
+19.8% avg upside
36 analysts
$558.00
39.00% Upside
 -5.3% ·
OMDA
Omada Health, Inc.
 Jun 10, 2026 BUY Strong Buy
+9.2% avg upside
12 analysts
$25.00
2.50% Upside
 +37.1% ·
MDT
Medtronic
 Jun 04, 2026 HOLD Buy
+6.4% avg upside
38 analysts
$83.00
8.42% Downside
 +13.0% ·
MMED
MiniMed Group, Inc.
 Jun 03, 2026 BUY Strong Buy
+10.7% avg upside
14 analysts
$24.00
19.89% Upside
 +41.3% ·
ABT
Abbott Laboratories
 May 31, 2026 BUY Strong Buy
+4.4% avg upside
36 analysts
$113.00
1.60% Upside
 +24.6% ·
HQY
Healthequity
 May 29, 2026 SELL Strong Buy
+8.0% avg upside
20 analysts
$88.00
16.73% Downside
 -19.0% ·
PODD
Insulet
 May 27, 2026 BUY Strong Buy
+48.7% avg upside
32 analysts
$205.00
40.00% Upside
 -1.8% ·
TDOC
Teladoc
 May 27, 2026 BUY Buy
+315.9% avg upside
38 analysts
$8.00
14.99% Upside
 +3.3% ·
COO
Cooper Co
 May 27, 2026 SELL Buy
+74.2% avg upside
21 analysts
$61.00
20.27% Downside
 -25.3% ·
GKOS
Glaukos
 May 25, 2026 BUY Strong Buy
-10.8% avg upside
21 analysts
$153.00
19.34% Downside
 +60.5% ·
DOCS
Doximity
 May 15, 2026 HOLD Buy
+29.7% avg upside
28 analysts
$24.00
9.67% Downside
 +30.7% ·
DXCM
Dexcom
 May 15, 2026 BUY Strong Buy
+16.1% avg upside
32 analysts
$80.00
12.62% Downside
 +45.6% ·
SI
Shoulder Innovations, Inc.
 May 13, 2026 BUY Strong Buy
+22.6% avg upside
5 analysts
$20.00
4.04% Upside
 +43.8% ·
LIVN
LivaNova
 May 06, 2026 HOLD Strong Buy
-0.9% avg upside
15 analysts
$72.00
12.38% Downside
 +24.1% ·
MDLN
Medline
 May 06, 2026 BUY Strong Buy
+31.8% avg upside
27 analysts
$50.00
40.46% Upside
 -14.9% ·
SOLV
Solventum Corporation
 May 05, 2026 SELL Buy
+5.8% avg upside
16 analysts
$66.00
23.71% Downside
 -28.3% ·
CARL
Carlsmed, Inc.
 May 05, 2026 BUY Strong Buy
+34.4% avg upside
6 analysts
$16.00
14.45% Upside
 +53.8% ·
SYK
Stryker
 May 01, 2026 HOLD Strong Buy
+8.2% avg upside
37 analysts
$361.00
5.90% Upside
 +16.0% ·
IRTC
Irhythm Technologies
 Apr 30, 2026 HOLD Strong Buy
+35.2% avg upside
20 analysts
$147.00
19.26% Upside
 -2.1% ·
GEHC
GE Healthcare Technologies Inc
 Apr 30, 2026 HOLD Strong Buy
+11.5% avg upside
22 analysts
 — +21.2% ·
BDX
Becton Dickinson
 Apr 10, 2026 HOLD Buy
+7.8% avg upside
25 analysts
$167.00
8.29% Downside
 +18.8% ·
KMTS
Kestra Medical Technologies Ltd.
 Apr 09, 2026 HOLD Strong Buy
+1.8% avg upside
9 analysts
$17.00
38.65% Downside
 +45.6% ·
ZBH
Zimmer Biomet Holdings
 Feb 10, 2026 SELL Buy
+15.1% avg upside
38 analysts
$88.00
11.61% Downside
 -10.7% ·
HAE
Haemonetics
 May 16, 2016 HOLD Buy
-15.1% avg upside
18 analysts
$29.00
67.84% Downside
 +48.9% ·
GMED
Globus Medical
 May 16, 2016 SELL Strong Buy
+7.3% avg upside
24 analysts
$21.00
75.53% Downside
 -34.9% ·
KMB
Kimberly Clark
 Nov 15, 2013 SELL Buy
+15.3% avg upside
30 analysts
$103.00
7.04% Downside
 -10.9% ·
🔒 28 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
David Roman — Frequently Asked Questions
How accurate are David Roman's stock ratings?
Based on the calls 13Foresight could measure, about 66% of David's ratings were profitable over a one-year hold, with an average return of +10.2% per rating, or +3.9% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is David ranked on 13Foresight?
David Roman is currently ranked #504 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does David cover?
David most recently has ratings on BBNX, BAX, BSX, MOBI, BLCO, TNDM, EW, ISRG, OMDA, MDT, MMED, ABT and 21 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.